Disentangling the Complexity of Cardiometabolic Diseases through Omics Techniques

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 2798

Special Issue Editors


E-Mail Website
Guest Editor
Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), Hospital Universitario Puerta del Mar, Universidad de Cádiz, 11009 Cádiz, Spain
Interests: metabolomics; metallomics; nutrition; exposome; obesity; gut microbiota
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Co-Guest Editor
Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), Hospital Universitario Puerta del Mar, Universidad de Cádiz, 11009 Cádiz, Spain
Interests: obesity; inflammation; oxidative stress; proteomics; metabolism

Special Issue Information

Dear Colleagues,

Cardiometabolic diseases encompass a cluster of common metabolic and cardiovascular conditions that typically share various interrelated risk factors, such as insulin resistance, dyslipidemia, or elevated blood pressure. Although these non-communicable diseases are often preventable, their high prevalence and the frequent concomitance of other adverse health consequences make them a major public health issue today. A complex spectrum of different factors is well known to be involved in these multifactorial disorders, including oxidative stress, inflammatory processes, endocrine and metabolic alterations, gut microbiota dysbiosis, and exogenous factors (e.g., diet, lifestyle habits, exposure to endocrine disruptors). Accordingly, widely covered omics techniques (e.g., metabolomics, proteomics, transcriptomics, metallomics) stand out as reliable and powerful approaches to elucidate the multifaceted mechanisms underlying the pathogenesis and progression of these diseases, as well as to study the efficacy of therapeutic interventions (e.g., pharmaceuticals, antioxidant dietary compounds).

The aim of this Special Issue is to gather original research papers and review articles focused on the development and application of omics techniques to disentangle the complexity of cardiometabolic diseases, with particular emphasis on oxidative-related processes. Works addressing the identification of gut microbial and exogenous-related risk factors (i.e., the exposome) in the development of cardiometabolic disorders are also welcome.

Dr. Raúl González-Domínguez
Alvaro Gonzalez-Dominguez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiometabolic diseases
  • obesity
  • diabetes
  • metabolic syndrome
  • oxidative stress
  • metabolomics
  • proteomics
  • transcriptomics
  • metallomics

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 5903 KiB  
Article
Metabolipidomic Analysis in Patients with Obstructive Sleep Apnea Discloses a Circulating Metabotype of Non-Dipping Blood Pressure
by Lucía Pinilla, Iván D. Benítez, Esther Gracia-Lavedan, Gerard Torres, Olga Mínguez, Rafaela Vaca, Mariona Jové, Joaquim Sol, Reinald Pamplona, Ferran Barbé and Manuel Sánchez-de-la-Torre
Antioxidants 2023, 12(12), 2047; https://doi.org/10.3390/antiox12122047 - 27 Nov 2023
Cited by 1 | Viewed by 1055
Abstract
A non-dipping blood pressure (BP) pattern, which is frequently present in patients with obstructive sleep apnea (OSA), confers high cardiovascular risk. The mechanisms connecting these two conditions remain unclear. In the present study we performed a comprehensive analysis of the blood metabolipidome that [...] Read more.
A non-dipping blood pressure (BP) pattern, which is frequently present in patients with obstructive sleep apnea (OSA), confers high cardiovascular risk. The mechanisms connecting these two conditions remain unclear. In the present study we performed a comprehensive analysis of the blood metabolipidome that aims to provide new insights into the molecular link between OSA and the dysregulation of circadian BP rhythmicity. This was an observational prospective longitudinal study involving adults with suspected OSA who were subjected to full polysomnography (PSG). Patients with an apnea–hypopnea index ≥ 5 events/h were included. Fasting plasma samples were obtained the morning after PSG. Based on the dipping ratio (DR; ratio of night/day BP values) measured via 24 h ambulatory BP monitoring, two groups were established: dippers (DR ≤ 0.9) and non-dippers (DR > 0.9). Treatment recommendations for OSA followed the clinical guidelines. Untargeted metabolomic and lipidomic analyses were performed in plasma samples via liquid chromatography–tandem mass spectrometry. Non-dipper patients represented 53.7% of the cohort (88/164 patients). A set of 31 metabolic species and 13 lipidic species were differentially detected between OSA patients who present a physiologic nocturnal BP decrease and those with abnormal BP dipping. Among the 44 differentially abundant plasma compounds, 25 were putatively identified, notably glycerophospholipids, glycolipids, sterols, and fatty acid derivates. Multivariate analysis defined a specific metabotype of non-dipping BP, which showed a significant dose-response relationship with PSG parameters of OSA severity, and with BP dipping changes after 6 months of OSA treatment with continuous positive airway pressure (CPAP). Bioinformatic analyses revealed that the identified metabolipidomic profile was found to be implicated in multiple systemic biological pathways, with potential physiopathologic implications for the circadian control of BP among individuals with OSA. Full article
Show Figures

Figure 1

17 pages, 3392 KiB  
Article
Prenylcysteine Oxidase 1 Is a Key Regulator of Adipogenesis
by Cristina Banfi, Alice Mallia, Stefania Ghilardi, Maura Brioschi, Erica Gianazza, Sonia Eligini, Pelin Sahlén and Roberta Baetta
Antioxidants 2023, 12(3), 542; https://doi.org/10.3390/antiox12030542 - 21 Feb 2023
Viewed by 1357
Abstract
The process of adipogenesis involves the differentiation of preadipocytes into mature adipocytes. Excessive adipogenesis promotes obesity, a condition that increasingly threatens global health and contributes to the rapid rise of obesity-related diseases. We have recently shown that prenylcysteine oxidase 1 (PCYOX1) is a [...] Read more.
The process of adipogenesis involves the differentiation of preadipocytes into mature adipocytes. Excessive adipogenesis promotes obesity, a condition that increasingly threatens global health and contributes to the rapid rise of obesity-related diseases. We have recently shown that prenylcysteine oxidase 1 (PCYOX1) is a regulator of atherosclerosis-disease mechanisms, which acts through mechanisms not exclusively related to its pro-oxidant activity. To address the role of PCYOX1 in the adipogenic process, we extended our previous observations confirming that Pcyox1−/−/Apoe−/− mice fed a high-fat diet for 8 or 12 weeks showed significantly lower body weight, when compared to Pcyox1+/+/Apoe−/− mice, due to an evident reduction in visceral adipose content. We herein assessed the role of PCYOX1 in adipogenesis. Here, we found that PCYOX1 is expressed in adipose tissue, and, independently from its pro-oxidant enzymatic activity, is critical for adipogenesis. Pcyox1 gene silencing completely prevented the differentiation of 3T3-L1 preadipocytes, by acting as an upstream regulator of several key players, such as FABP4, PPARγ, C/EBPα. Proteomic analysis, performed by quantitative label-free mass spectrometry, further strengthened the role of PCYOX1 in adipogenesis by expanding the list of its downstream targets. Finally, the absence of Pcyox1 reduces the inflammatory markers in adipose tissue. These findings render PCYOX1 a novel adipogenic factor with possible pathophysiological or therapeutic potential. Full article
Show Figures

Figure 1

Back to TopTop